Non-profit research institute announces the release of the latest version of its flagship DILI platform

RESEARCH TRIANGLE PARK, NC – DILIsym Services Inc. (www.dilisymservices.com) announces the release of DILIsym® v4B. DILIsym® software is developed and released as part of the DILI-sim Initiative (www.dilisym.com), an effort to develop a mathematical, mechanistic model of drug-induced liver injury chaired by Dr. Paul B. Watkins. DILIsym® v4B was made available to all DILI-sim Initiative industry members as of September 3, 2015.

DILIsym® v4B introduces an entirely new and improved graphical user interface (GUI).  With the new GUI, model simulations are more easily reproduced, changes to parameter sets are more readily tracked, inputs and outputs can be organized better into panels, and results are more easily exported to Excel.  The GUI also features the ability to use PK simulation results from other software platforms to drive liver toxicity predictions, and contains built-in ‘eDISH’ plot capability.

Additional capabilities and improvements include:

·         New ASBT (gut transporter) inhibition module for bile acids

·         Updated cytokeratin 18 parameter values based on new data

·         Updated secondary necrosis function to be more biologically realistic, based on new data

·         Additional SimPops™, capturing impact of variability in key pathways


ABOUT THE DILI-SIM INITIATIVE

The DILI-sim Initiative is a pre-competitive partnership between DILIsym Services Inc. and a diverse set of stakeholders to develop a computational model that will predict whether new drug candidates will cause drug-induced liver injury (DILI) in patients. The goals of the Initiative are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs. It is the intent of the DILI-sim Initiative to make the model, in the form of DILIsym® software, broadly available so that it may be used by the pharmaceutical industry and other entities in academia, government, and industry. The Initiative is led by Dr. Paul B. Watkins, Director of the University of North Carolina Institute for Drug Safety Sciences, located in the heart of Research Triangle Park, North Carolina. For more information, please visit www.dilisym.com.

ABOUT DILISYM SERVICES INCORPORATED

DILIsym Services, Inc. was incorporated in 2015 and is operated in Research Triangle Park, North Carolia. DILIsym Services, Inc. is a startup company committed to providing the pharmaceutical industry with the tools, resources, and information to efficiently develop safer drug therapies that increase the availability of vital therapeutics for the patients who need them. DILIsym Services, Inc.applies the DILIsym® software to improve the safety profiles of therapeutics reaching the market. 

For more information, please visit www.dilisymservices.com